| Filed On | Filing |
|---|---|
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests |
| 23 Sep 2026 |
Form 4: Denton John Russel, See Remarks
Sold 7,500 shares ($239K) |
| 22 Sep 2026 | 144 |
| 17 Sep 2026 |
Form 4: Brille Brian J, Director
Received 400,000 shares by exercise or conversion ($976K) · Sold 400,000 shares ($12.1M) |
| 17 Sep 2026 | 144 |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Beginning on September 14, 2026, representatives of Caris Life Sciences, Inc. (the “Company”) intend to use an investor presentation (the “Investor Presentation”) in meetings with current and potential investors at the Morgan Stanley 24t... |
| 04 Sep 2026 |
Form 4: Spetzler David Baxley, President
Received 1,000,000 shares by exercise or conversion ($2.44M) · Sold 478,000 shares ($11.9M) · Received 250,000 shares by exercise or conversion ($610K) · 1 more |
| 04 Sep 2026 | 144 |
| 03 Sep 2026 | 144 |
| 24 Aug 2026 | 144 |
| 14 Aug 2026 |
Form 4: Castleman Peter M, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Phillips T Danny, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Minor Lloyd, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Gilliam Joseph E, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Fredrickson David Paul, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Vacirca Jeff L, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Johansen Laura I, Director
Received 13,192 shares as a grant or award |
| 14 Aug 2026 |
Form 4: Halbert Jon, Director
Received 13,192 shares as a grant or award |
Loading...